Back
Rate this talk
Your peers have not rated this talk yet.
15-minute watch | Talk 1 of 3

EU CAR T: Kite symposium

How has CAR T changed survival outcomes in LBCL so far?

Dr Pere Barba, Prof. Peter Vandenberghe
SYMPOSIUM
EU CAR T

Dr Pere Barba
Vall d’Hebron University Hospital, Barcelona, Spain

Prof. Peter Vandenberghe
University Hospital Leuven, Leuven, Belgium

Dr Pere Barba of Vall d'Hebron University Hospital, Barcelona, Spain gives an overview of RW data on attrition rates prior to CAR T, while Prof. Vandenberghe of University Hospital Leuven, Leuven, Belgium, discusses the impact of CAR T on survival outcomes in LBCL

Read more

Talks in this series

How has CAR T changed survival outcomes in DLBCL so far?
15-minute watch | Talk 1 of 3
EU CAR T: Kite symposium
How has CAR T changed survival outcomes in LBCL so far?
How has CAR T changed survival outcomes in DLBCL so far?
15-minute watch
EU CAR T: Kite symposium

How has CAR T changed survival outcomes in LBCL so far?

How can we improve survival outcomes in R_R LBCL?
15-minute watch | Talk 2 of 3
How can we improve survival outcomes in R/R LBCL?
Dr Cathy Burton
How can we improve survival outcomes in R_R LBCL?
15-minute watch

How can we improve survival outcomes in R/R LBCL?

Dr Cathy Burton

How can we deliver on survival for patients?
7-minute watch | Talk 3 of 3
How can we deliver on survival for patients?
Dr Pere Barba
How can we deliver on survival for patients?
7-minute watch

How can we deliver on survival for patients?

Dr Pere Barba

How has CAR T changed survival outcomes in DLBCL so far?
15-minute watch | Talk 1 of 3
EU CAR T: Kite symposium
How has CAR T changed survival outcomes in LBCL so far?
How has CAR T changed survival outcomes in DLBCL so far?
15-minute watch
EU CAR T: Kite symposium

How has CAR T changed survival outcomes in LBCL so far?

How can we improve survival outcomes in R_R LBCL?
15-minute watch | Talk 2 of 3
How can we improve survival outcomes in R/R LBCL?
Dr Cathy Burton
How can we improve survival outcomes in R_R LBCL?
15-minute watch

How can we improve survival outcomes in R/R LBCL?

Dr Cathy Burton

How can we deliver on survival for patients?
7-minute watch | Talk 3 of 3
How can we deliver on survival for patients?
Dr Pere Barba
How can we deliver on survival for patients?
7-minute watch

How can we deliver on survival for patients?

Dr Pere Barba

Interested in this topic?

Find more like this

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.